NazemAtassiMD
Neurology • Burlington, MANeuromuscular Medicine
Assistant Professor of Neurology, Massachusetts General Hospital
Are you Dr. Atassi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 40 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
41 Mall Rd
# Lahey
Burlington, MA 01805Phone+1 617-643-0842- Is this information wrong?
Summary
- Dr. Nazem Atassi, MD is a board certified neurologist in Burlington, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Massachusetts General Hospital and is an Assistant Professor of Neurology at Massachusetts General Hospital.
Education & Training
Boston University Medical CenterResidency, Neurology, 2004 - 2007- Boston University Medical CenterInternship, Internal Medicine, 2003 - 2004
Damascus University Faculty of MedicineClass of 2002
Certifications & Licensure
MA State Medical License 2008 - 2025- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis Start of enrollment: 2009 Jan 01
- Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2012 Jan 01
- Gilenya in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsSafety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants.Agnes Hincelin-Mery, Xavier Nicolas, Cathy Cantalloube, Robert Pomponio, Pascale Lewanczyk, Myriam Benamor, Dimitry Ofengeim, Emmanuel Krupka, Jennifer Hsiao-Nakamoto,...> ;Clinical and Translational Science. 2024 Jan 1
- 2 citationsAn innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneu...Luis Querol, Richard A Lewis, Hans-Peter Hartung, Pieter A Van Doorn, Erik Wallstroem, Xiaodong Luo, Miguel Alonso-Alonso, Nazem Atassi, Richard A C Hughes> ;Journal of the Peripheral Nervous System. 2023 Jun 1
- 5 citationsSelective atrophy of the cervical enlargement in whole spinal cord MRI of amyotrophic lateral sclerosis.Robert L Barry, Angel Torrado-Carvajal, John E Kirsch, Grae E Arabasz, Daniel S Albrecht, Zeynab Alshelh, Olivia Pijanowski, Austin J Lewis, Mackenzie Keegan, Beverly ...> ;Neuroimage. Clinical. 2022 Jan 1
- Join now to see all
Press Mentions
MediciNova Announces Full Enrollment in ALS Biomarker Clinical TrialJuly 29th, 2018
New Imaging Protocol Could Vastly Accelerate Clinical Trials for New ALS TreatmentsMay 31st, 2018- Mass General Investigators on the Cutting Edge of ALS ResearchMay 10th, 2018
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
